Challenges of immunogenicity assays for vaccines

Bioanalysis

Volumn 4, Issue 4, 2012, Pages 397-406

  Kostense, Stefan ^a   Hendriks, Jenny ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

CELLULAR IMMUNITY; CYTOKINE RELEASE; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; PRACTICE GUIDELINE; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; REVIEW; VACCINE PRODUCTION; VALIDATION PROCESS;

ANTIBODIES; ANTIBODY FORMATION; BIOLOGICAL ASSAY; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; PRACTICE GUIDELINES AS TOPIC; VACCINES; VALIDATION STUDIES AS TOPIC;

EID: 84858036057     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.327     Document Type: Review

References (31)

1. WHO. Biomarkers in risk assessment: validity and validation. IPCS (2001).
2. Biomarker Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001). Clear overview of the terminology and definitions used in the biomarker field.
3. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47(3), 401-409 (2008). Excellent view and review on the importance of correlates of protection in the control of infectious diseases, including definitions and terminology.
4. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between hemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010).
5. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J. Infect. Dis. 179(2), 489-492 (1999).
6. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35(1), 69-75 (1979).
7. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4(1), 25-36 (1996).
8. Fletcher HA. Correlates of immune protection from tuberculosis. Curr. Mol. Med. 7(3), 319-325 (2007).
9. Kagina BM, Abel B, Scriba TJ et al. Specific T-cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after Bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182(8), 1073-1079 (2010).
10. Weinberg A, Song Ly, Wilkening CL et al. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J. Immunol. Methods 363(1), 42-50 (2007).
11. De Rosa SC, Lu FX, Yu J et al. Vaccination in humans generates broad T-cell cytokine responses. J. Immunol. 173(9), 5372-5380 (2004). Highlights the importance of analyzing multiple phenotype- and activation-markers of T cells after natural infection and after vaccination in a set of important disease models.
12. + T cells. Blood 107(12), 4781-4789 (2006).
13. Kostense S, Mommaas B, Hendriks J et al. A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines. Clin. Vaccine Immunol. 18(5), 776-782 (2011).
14. Sprangers MC, Lakhai W, Koudstaal W et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41(11), 5046-5052 (2003).
15. Maecker HT, Moon J, Bhatia S et al. Impact of cryopreservation on tetramer, cytokine flow cytometry and ELISPOT. BMC Immunol. 6, 17 (2005). Comprehensive study on critical factors influencing the integrity of peripheral blood mononuclear cell samples.
16. Dyer WB, Pett SL, Sullivan JS et al. Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples. Clin. Vaccine Immunol. 14(1), 52-59 (2007).
17. Bull M, Lee D, Stucky J et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 322(1-2), 57-69 (2007).
18. US FDA: Guidance for Industry. Bioanalytical Method Validation (2001). Early and widely followed regulatory guideline that serves as the basic validation guideline for many sorts of assays.
19. ICH: Validation of analytical procedures: text and methodology. Analytical Validation Q2(R1) (2005). A widely followed guideline that serves as the basic validation guideline for many sorts of assays.
20. Findlay JW, Smith WC, Lee JW et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21(6), 1249-1273 (2000).
21. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
22. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
23. European Medicines Agency. Guidelines on Validation of Bioanalytical Methods (2011). Most up-to-date regulatory guideline on assay validation and sample analysis for measuring drug concentrations in clinical study samples.
24. European Medicines Agency. Guidelines on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (2008).
25. US FDA. Guidance for Industry: assay development for immunogenicity testing of therapeutic proteins (2009).
26. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006). Comprehensive and informative conference report discussing the practical and regulatory issues of biomarker development and validation.
27. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004).
28. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
29. Czerkinsky CC, Nilsson La, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 65(1-2), 109-121 (1983).
30. Czerkinsky CC, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110(1), 29-36 (1988).
31. Querec Td, Akondy Rs, Lee Ek et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).